

AWARD NUMBER: W81XWH-20-1-0495

TITLE: Cold-Stored Platelets to Treat Bleeding in Cardiac Surgery Patients

PRINCIPAL INVESTIGATOR: Moritz Stolla, MD

CONTRACTING ORGANIZATION: Bloodworks Northwest, Seattle, WA

REPORT DATE: October 2023

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Development Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.



## TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	2
2. Keywords	2
3. Accomplishments	2
4. Impact	7
5. Changes/Problems	7
6. Products	8
7. Participants & Other Collaborating Organizations	8
8. Special Reporting Requirements	9
9. Appendices	10

## 1. Introduction

The objective of this clinical trial is to assess the feasibility of the study protocol and preliminarily test the efficacy and safety of platelets stored at cold conditions (1-6°C) in 100% plasma for 10-14 days (CSP) in cardiac surgery patients who are actively bleeding and require platelet transfusion. The control treatment arm will receive platelets stored at room temperature (20-24°C) in 100% plasma (RSP) for up to 7 days. In this preliminary study, we are also clarifying critical mechanistic questions related to the nature of the platelet defect in the patient population under study and the post-transfusion function of stored platelets utilizing specialized laboratory assays. We hypothesize that 1) CSP are more effective than RSP at reducing blood loss and improving platelet function in subjects actively bleeding due to cardiac surgery with cardiopulmonary bypass (CPB), and that 2) CSP are safe and do not lead to increased risks relative to RSP. The overarching goal of our investigations is to evaluate the role of cold stored platelets for any actively bleeding subject with a potential platelet defect, including trauma subjects. *If our hypotheses can be supported by data, our study, together with larger follow-on studies, could have a practice-changing impact.*

## 2. Keywords

Platelets, transfusion, bleeding, RSP – Room temperature stored platelets (current clinical standard control platelets), CSP – Cold stored platelets (investigational platelets)

## 3. Accomplishments

### What were the major goals of the project?

Specific Aim 1: To assess the feasibility of the study protocol.

Specific Aim 2: To obtain data regarding the relative efficacy of CSP compared to RSP.

Specific Aim 3: To obtain data regarding the relative safety of CSP compared to RSP.

Statement of Work (updated approved version dated 30Sep2022)	Timeline	Status (% completed, date)
<b>Major Task 1: Study Required Regulatory Approvals</b>	Months	
Coordinate with Clinical Site for subaward agreement	1-2	Completed (not applicable)
PI will complete Investigator Agreement relevant to the entire conduct of the study at all sites.	2-3	Completed (100%, 31Mar2022)
Budgets reviewed and finalized	1-2	Completed (100%, 18May2021)
Investigational New Drug (IND) application initial approval to the U.S. Food and Drug Administration	Approval obtained 05/2019	Completed (100%, 22May2019)
IND follow-up to approval with all desired changes	1-3	Completed (100%, 15Jul2021)
Provide SMC with the Study Protocol and Informed Consent Form (ICF) template	1-2	Completed (100%, 30Jun2021)
SMC - IRB protocol submission and review	2-4	Completed (100%, Jul2021)
Funding agency HRPO review submission and review	4-5	Completed (100%, 08Oct2021) Annual renewal Jan 2023
Submit any study protocol or ICF amendments to the IRB	As needed	Annual review approval Jan2023
Submit any study protocol amendments or ICF amendments to the funding agency HRPO (when appropriate)	As needed	As needed
Submit any study protocol amendments or safety updates to the FDA (for IND) as required	As needed	As needed

### Annual Report 2022-2023

AWARD NUMBER: W81XWH-20-1-0495

TITLE: Cold-Stored Platelets to Treat Bleeding in Cardiac Surgery Patients

PRINCIPAL INVESTIGATOR: Moritz Stolla, MD

Coordinate with Clinical Site for annual and other required regulatory reporting (IRB, HRPO, IND)	Annually and as needed	Ongoing / As needed
<i>Milestone Achieved: Study contract(s) signed and site budget approved</i>	2	Completed (100%, 05Aug2021)
<i>Milestone Achieved: IND approval</i>	2	Completed (100%, 18May2021)
<i>Milestone Achieved: Local IRB approval</i>	3-4	Completed (100%, 12Aug2021)
<i>Milestone Achieved: HRPO approval for protocol and ICF</i>	4-5	Completed (100%, 08Oct2021)
	<b>Timeline</b>	<b>Status (% completed, date)</b>
<b>Major Task 2: Process Set-Up, Development of Study Tools and Training for Implementing Study Procedures</b>	Months	
Manufacturing implementation of per-protocol CSP manufacturing with the South Texas Blood & Tissue Center and/or Bloodworks Northwest	1-4 months	Completed (100%, 28Feb2022)
BWNW-SMC TSL staff process development and training on study platelet product ordering, receiving, processing, documenting, blinding, and issuing	2-6	Completed (100%, 28Feb2022)
Process development for documenting, ordering, and transfusing blinded study platelet products for BWNW-SMC TSL staff, SMC research personnel, and clinical staff.	2-6	Completed (100%, 28Feb2022)
Arrange for research laboratory testing sample collection, transportation, and testing	4	Completed (100%, 28Feb2022)
Research laboratory staff training as necessary for receiving samples, testing, reporting requirements and source document management	3-5	Completed (100%, Feb2022)
Develop case report forms (CRF) and electronic data capture (EDC) tools as needed to record all study measurements	3-6	Completed (100%, 12/2021)
Training for staff required to complete and verify entries on CRF and EDC system	5-6	Completed (100%, 11/2021)
Study personnel training (SMC): training for all Clinical Site research personnel and appropriate clinical staff (includes Site Initiation Visit and associated trainings)	5-6	Completed (100%, Feb2022)
Study personnel training (BWNW): training for all appropriate BWNW research staff (includes Site Initiation Visit and associated trainings)	3-6	Completed (100%, Feb2022)
Study personnel are delegated for their assigned study responsibilities by the PI	5-6	Completed (100%, Feb2022)
<i>Milestone Achieved: Processes for study implementation are set-up and validated</i>	5-6	Completed (100%, Mar2022)
<i>Milestone Achieved: All study personnel are trained and appropriately delegated for their assigned responsibilities</i>	5-6	Completed (100%, Mar2022)
	<b>Timeline</b>	<b>Status (% completed, date)</b>
<b>Major Task 3: Study Enrollment</b>	Months	Ongoing (60%, Sep2023)
<b>Major Task 4: Data Analysis</b>	Months	
<b>Major Task 5: Study Close-Out</b>	Months	

**Annual Report 2022-2023**

AWARD NUMBER: W81XWH-20-1-0495

TITLE: Cold-Stored Platelets to Treat Bleeding in Cardiac Surgery Patients

PRINCIPAL INVESTIGATOR: Moritz Stolla, MD

## What was accomplished under these goals?

### Major Task 1: Study Required Regulatory

#### Approvals

All key critical items of Major Task 1 are completed.

In Year 3 the Continued approval was obtained by both the IRB and HRPO.

### Major Task 2: Process Set-Up, Development of Study Tools and Training for Implementing Study Procedures

Ongoing protocol training with the clinical research team and transfusion lab at Swedish Medical Center-Cherry Hill occurred in the past year.

Cold-stored platelet (research product) issues were discussed with South Texas Blood and Tissue Center.

Lab protocols and specimen processing was discussed with the Stolla Research lab at Bloodworks NW.

### Major Task 3: Study Enrollment

Study enrollment began Year 2, Q2. Study enrollment was initially slow and numerous strategies were implemented to improve this. The last quarter of this year had a significant increase in enrollment and we have passed the halfway point in enrollment.

Significant progress has been made in the development of the HLA differentiated functional assay. The functional assay has been well tested to work with five different functional markers under two different agonist, each at two different concentrations, as well as no-agonist controls. Four different HLA antibodies have been tested and calibrated to work with the functional assay, along with a pan-platelet marker. The preliminary troubleshooting, workflow, and proof of concept work has been completed, 18 subjects have been transfused and have evaluable data from the still evolving exploratory assay. More work is still needed to optimize agonist concentration as well as gating strategies, as the blood form recently transfused cardiac surgery patients has characteristics that are hard to replicate using normal donors; we are optimistic that this will be achievable with more subjects in the future.

### Major Task 4: Data Analysis

Data analysis activities is not initiated until Major Task 3 is completed.

### Major Task 5: Study Close-out

Study close-out is not initiated until the study database is locked after the end of subject enrollment.

**Summary and Conclusion:** The project team has made significant progress with enrollment as we passed the 50% enrollment mark. We do continue to have issues with aggregate formation in the cold stored platelets received from South Texas. This has improved in the last quarter.

### Regulatory Protocol and Activity Status

#### **PROTOCOL (1 of 1 total):**

Protocol Number: 2021-01

#### **Annual Report 2022-2023**

AWARD NUMBER: W81XWH-20-1-0495

TITLE: Cold-Stored Platelets to Treat Bleeding in Cardiac Surgery Patients

PRINCIPAL INVESTIGATOR: Moritz Stolla, MD

HRPO Log Numbers: E01348.1a (Bloodworks Northwest Research Institute) and E01348.1b (Swedish Medical Center-Cherry Hill)

Title: Evaluation of Efficacy and Safety of Extended Cold Stored Apheresis Platelets versus Conventional Apheresis Platelets in Cardiac Surgery Patients (CHASE Trial)

Target evaluable subjects required for statistical significance: Unspecified in statistical plan (primary endpoint is feasibility)

Target approved: 30 evaluable subjects (up to 100 enrolled).

**Submitted to and approved by:**

FDA – IND #18981

- Initial submission: 08Apr2019
  - Approval: 22May2019
- Annual report submission (2020): 21Jul2020
- Ind protocol modification submission: 07May2021
  - Approval: 15Jul2021
- Annual report submission (2021): 09Jul2021
- FDA form 1572 modification submission: 24Sep2021
- Ind protocol modification submission: 04Jan2022
  - Approval 17Feb2022
- Annual report submission (2023): 27Jul2023

IRB – Providence St. Joseph IRB (PSJ-IRB)

- Initial submission: 02Jul2021--Approval: 12Aug2021
- Modification #1 Approval 24Nov2021
- Modification #2 Approval 10Dec2021
- Modification #3 Approval 25Jan2022
- Modification #4 Approval 01Mar2022
- Modification #5 Approval 08Aug2022
- Modification #6 Approval 10Oct2022
- Annual Review Approval 24Jan2023

HRPO [HRPO Log Numbers: E01348.1a (Bloodworks Northwest Research Institute) and E01348.1b (Swedish Medical Center-Cherry Hill)]

- Initial submission: 17Aug2021-- approval: 08Oct2021
- Annual Review: approval Jan2023

**STATUS: Y2 (2022-2023)**

- (i) Number of subjects recruited/original planned target: 35/38  
 Number of subjects screened/original planned target: 72/no screening target in SOW  
 Number of patients enrolled/original planned target: 35/38  
 Number of patients completed/original planned target: 35/38

--	--

**Annual Report 2022-2023**

AWARD NUMBER: W81XWH-20-1-0495

TITLE: Cold-Stored Platelets to Treat Bleeding in Cardiac Surgery Patients

PRINCIPAL INVESTIGATOR: Moritz Stolla, MD

<u>Protocol Number</u>	<u>Protocol PI Name</u>	<u>Organization (Site)</u>	<u># Target</u>	<u># Enrolled</u>	<u># Completed</u>	<u># Evaluable (received platelets during the study window)</u>
2021-01	Moritz Stolla, MD	E01348.1b (Swedish Medical Center-Cherry Hill)				
This reporting period			18	30	30	14
Cumulative			38	35	25	18

<u>Protocol Number</u>	<u>Protocol PI Name</u>	<u>Organization (Site)</u>	<u># Target</u>	<u># Enrolled</u>	<u># Completed</u>	<u># Evaluable (received platelets during the study window)</u>
2021-01	Moritz Stolla, MD	E01348.1a (Bloodworks NW)				
This reporting period			0	0	0	0
Cumulative			0	0	0	0

**What opportunities for training and professional development has the project provided?**

Nothing to Report.

**How were the results disseminated to communities of interest?**

Nothing to Report.

**What do you plan to do during the next reporting period to accomplish the goals?**

During the next reporting year (Q4 2023-Q3 2024), we have the following goals broken down by reporting quarter.

**Q4 2023:** We aim to continue study enrollment and subject accrual during the quarter with targeted enrollment of at least 6 subjects per month. We plan to convene DSMB for evaluation of study status in Nov 2023.

**Q1 2024:** We aim to continue study enrollment and subject accrual during the quarter with targeted enrollment of at least 6 subjects per month. We tentatively aim to submit a methods manuscript describing the developed HLA exploratory functional assay in Q1 2024.

**Q2 2024:** We aim to continue study enrollment and subject accrual during the quarter with targeted enrollment of at least 6 subjects per month.

**Q3 2024:** We hope to have enrollment completed and data analysis started.

**Annual Report 2022-2023**

AWARD NUMBER: W81XWH-20-1-0495

TITLE: Cold-Stored Platelets to Treat Bleeding in Cardiac Surgery Patients

PRINCIPAL INVESTIGATOR: Moritz Stolla, MD

#### **4. Impact**

**What was the impact on the development of the principal discipline(s) of the project?**

Nothing to Report.

**What was the impact on other disciplines?**

Nothing to Report.

**What was the impact on technology transfer?**

Nothing to Report.

**What was the impact on society beyond science and technology?**

Nothing to report.

#### **5. CHANGES/PROBLEMS:**

##### **Changes in approach and reasons for change**

There continues to be an issue with aggregate formation in the CSP received from South Texas. We spoke with other researchers using this product and the consensus is that the issue is the collection kits that are being used. We did, however see this issue decrease in the last quarter. Nevertheless, the randomization is impacted by this and we moved to the forced-randomization plan in order to even the randomization. We will discuss with the DSMB during the upcoming meeting.

##### **Actual or anticipated problems or delays and actions or plans to resolve them**

As subjects are enrolled, we continue to adjust the exploratory assay (HLA discriminating functional assessment of transfused platelets flow cytometry assay).

See above for comments about the randomization.

##### **Anticipated Problems/Issues**

Nothing to discuss.

##### **Changes that had a significant impact on expenditures**

Costs were lower than anticipated because enrollment did not occur in until Q1 2022. We anticipate increased costs in future reporting periods where such enrollment associated costs will be increased.

##### **Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

##### **Significant changes in use or care of human subjects**

Nothing to Report.

##### **Significant changes in use or care of vertebrate animals**

#### **Annual Report 2022-2023**

AWARD NUMBER: W81XWH-20-1-0495

TITLE: Cold-Stored Platelets to Treat Bleeding in Cardiac Surgery Patients

PRINCIPAL INVESTIGATOR: Moritz Stolla, MD

Nothing to Report.

**Significant changes in use of biohazards and/or select agents**

Nothing to Report.

**6. PRODUCTS:**

- **Publications, conference papers, and presentations**

Nothing to Report.

**Journal publications**

Nothing to Report.

**Books or other non-periodical, one-time publications.**

Nothing to Report.

**Other publications, conference papers and presentations.**

Nothing to Report.

- **Website(s) or other Internet site(s)**

Nothing to Report.

- **Technologies or techniques**

Nothing to Report.

- **Inventions, patent applications, and/or licenses**

Nothing to Report.

- **Other Products**

Nothing to Report.

**7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS**

**What individuals have worked on the project?**

Name: Moritz Stolla, MD  
No change

Name: Jeffrey A Miles, BA, MS  
No longer working on this project.

Name: Patricia Klotz, BSN  
No change

**Annual Report 2022-2023**

AWARD NUMBER: W81XWH-20-1-0495

TITLE: Cold-Stored Platelets to Treat Bleeding in Cardiac Surgery Patients

PRINCIPAL INVESTIGATOR: Moritz Stolla, MD

Name: Shawn Bailey, BS  
No change

Name: Jennifer Nagel, BS  
No longer working on this project

Name: Inger Rasmussen, BA  
No longer working on this project

Name: Caroline Petgrave, BA  
No change

Name: Andrea Drouhard, BA  
No longer working on this project.

Name: Elizabeth Borchard  
Research Coordinator, Swedish Medical Center-Cherry Hill

Name: Michelle Poitevin  
Research Coordinator, Swedish Medical Center-Cherry Hill

**Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

Nothing to Report

**What other organizations were involved as partners?**

Organization Name: Swedish Medical Center – Cherry Hill

Location of Organization: 500 17<sup>th</sup> Avenue, Seattle, WA, 98122

Partner's contribution to the project: collaboration

Description: Swedish Medical Center – Cherry Hill is the clinical site for this project's only clinical study protocol and they are a sub awardee of this project. Their research staff completes site Research Coordinator and other related site research activities.

Organization Name: South Texas Blood and Tissue Center

Location of Organization: 6211 I-10, San Antonio, TX 78201

Partner's contribution to the project: Other

Description: The South Texas Blood & Tissue Center provides a licensed CSP product for use as an investigational product in the CHASE Trial.

## 8. SPECIAL REPORTING REQUIREMENTS

**COLLABORATIVE AWARDS:** *For collaborative awards, independent reports are required from BOTH the Initiating Principal Investigator (PI) and the Collaborating/Partnering PI. A duplicative report is acceptable; however, tasks shall be clearly marked with the responsible PI and research site. A report shall be submitted to <https://ebrap.org/eBRAP/public/index.htm> for each unique award.*

**QUAD CHARTS:** *If applicable, the Quad Chart (available on <https://www.usamraa.army.mil/Pages/Resources.aspx>) should be updated and submitted with attachments.*

The Quad Chart has been appropriately included as indicated.

### Annual Report 2022-2023

AWARD NUMBER: W81XWH-20-1-0495

TITLE: Cold-Stored Platelets to Treat Bleeding in Cardiac Surgery Patients

PRINCIPAL INVESTIGATOR: Moritz Stolla, MD

- 9. APPENDICES:** *Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.*

The following historical patient procedure type data is reproduced from email correspondence received by Bloodworks Northwest from Bob Fletcher at Swedish Medical Center – Cherry Hill on March 23, 2021:

Updated Clinical Site (Swedish Medical Center – Cherry Hill) Procedure Volume

Surgery Type	2017	2018	2019	2020	Annual Avg
Re-do surgeries	36	45	28	37	36.5
Triple valve	9	9	6	0	6
Complex aortic surgery	59	66	61	38	56
All	104	120	95	75	98.5*

\*Adjusting for cases falling in multiple categories (i.e., unique patients): 83 per year

**Annual Report 2022-2023**

AWARD NUMBER: W81XWH-20-1-0495

TITLE: Cold-Stored Platelets to Treat Bleeding in Cardiac Surgery Patients

PRINCIPAL INVESTIGATOR: Moritz Stolla, MD